Marché des maladies rétiniennes héréditaires en Amérique du Nord – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et perspectives du marché : Marché des maladies rétiniennes héréditaires en Amérique du Nord

Les maladies rétiniennes héréditaires (ou MRI) sont un groupe de maladies qui peuvent entraîner une perte de vision grave, voire la cécité. Chaque MRI est causée par au moins un gène qui ne fonctionne pas comme il le devrait. Les MRI peuvent toucher des individus de tous âges, peuvent progresser à des rythmes différents et sont rares. Cependant, beaucoup sont dégénératives, ce qui signifie que les symptômes de la maladie s'aggraveront avec le temps. Les types courants de MRI comprennent l'amaurose congénitale de Leber (LCA), la rétinite pigmentaire, la choroïdérémie, la maladie de Stargardt et l'achromatopsie. L'objectif de la thérapie génique est de corriger ou de compenser le gène défectueux. Les MRI sont des candidats particulièrement forts pour les traitements de thérapie génique, en raison de la constitution physique unique de la rétine . Comparé à d'autres organes du corps, l'œil est petit et facile d'accès pour l'administration du traitement. Cependant, certaines zones du corps sont privilégiées sur le plan immunitaire, ce qui signifie que la réponse immunitaire normale n'est pas aussi active. Ce type de greffe se situe généralement dans des zones très importantes de notre corps, qui peuvent être endommagées en cas de gonflement ou d'inflammation. Cela signifie que tout ce qui est implanté dans l'œil (une cellule avec un gène corrigé, par exemple) a moins de chances d'être rejeté.

Le diagnostic et le traitement des maladies rétiniennes héréditaires reposent sur diverses techniques qui permettent de diagnostiquer les maladies rétiniennes héréditaires après l'approbation du produit. Le traitement de la maladie a été récemment approuvé, ce qui soutient la croissance du marché.

Les maladies rétiniennes héréditaires sont favorables et visent à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché des maladies rétiniennes héréditaires connaîtra un TCAC de 7,6 % au cours de la période de prévision de 2022 à 2029.

Inherited Retinal Diseases Market Dynamics

Drivers

• Increase in the prevalence of Inherited Retinal Diseases

The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000 affecting two million people online.

• Increasing in Pipeline Products

As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the North America inherited retinal diseases market.High prevalence of genetic conditions

Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of inherited retinal diseases market.

Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counselling will positively impact the inherited retinal diseases market's growth rate. Additionally, high disposable income, rising number of cases of  various retinal diseases will result in the expansion of inherited retinal diseases market. 

Opportunities

• Increase in Government Initiatives Towards Inherited Retinal Disease.

Moreover, the increase in awarenss and treatment seeking rate and emerging reimbursent policies for the treatment will boost new opportunities for the market's growth rate.

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate inherited retinal diseases market in future.

Restraints/Challenges

However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of inherited retinal diseases market. Additionally, lack of enough qualified professionals, and complications involved with the disease will hinder the inherited retinal diseases market growth.

This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.

Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 0.06% and 0.2%, with a North America IRD caseload in the range of 5–10 million individuals.

Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Post COVID-19 Impact on Inherited Retinal Diseases Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

• In January 2022, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, has announced the launch of the Diana Davis Spencer Foundation Enhanced Translational Research Acceleration Program.

North America Inherited Retinal Diseases Market Scope

The inherited retinal diseases market is segmented into disease type, type, end-user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Disease Type

• Retinitis Pigmentosa
•  Stargardt’s Disease 
•  Achromatopsia
•  Cone-Rod Dystrophy
•  Choroideremia
•  Leber Congenital Amaurosis (LCA)  
•  Macular Edema
•  Others

On the basis of type, the inherited retinal diseases market is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others

Type

• Diagnosis
• Therapy

On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam

End User

• Hospitals
• Specialty Clinics
• Ambulatory surgical center
• Home Healthcare
• Others

On the basis of end-users, the inherited retinal diseases market is segmented into hospitals, specialty clinics, ambulatory surgical center, home healthcare and others

Distribution Channel

• Retail Sales
• Direct Tender

The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.

Pipeline Analysis

The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.

Inherited Retinal Diseases Market Regional Analysis/Insights

The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.

The countries covered in the inherited retinal diseases market report are U.S., Canada and Mexico in North America.

U.S. dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Inherited Retinal Diseases Market Share Analysis

The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.

Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson,  IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.

Research Methodology: North America Inherited Retinal Diseases Market

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse de la part de marché Amérique du Nord/régionale et des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.

SKU-67950